Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Fineline Cube Aug 5, 2026
Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Fineline Cube Aug 5, 2026
Company Drug

WinHealth Pharma Receives NMPA Approval for Glycerol Phenylbutyrate for Urea Cycle Disorders

Fineline Cube Jun 20, 2023

China-based Hong Kong WinHealth Pharma Group Ltd has announced receiving market approval from the National...

Company Drug

Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial

Fineline Cube Jun 19, 2023

China-based Nanjing Leads Biolabs Co., Ltd has revealed that it has received Investigational New Drug...

Company

AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions

Fineline Cube Jun 19, 2023

According to a report from the UK newspaper The Financial Times (FT), AstraZeneca (AZ, NASDAQ:...

Company Drug

TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody

Fineline Cube Jun 19, 2023

China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the US...

Company Drug

IASO Bio Receives FDA IND Approval for IASO-782 for Autoimmune Disorders

Fineline Cube Jun 19, 2023

China-based IASO Bio has announced that the US Food and Drug Administration (FDA) has approved...

Company Deals

Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics

Fineline Cube Jun 19, 2023

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully...

Company Deals

Acotec Scientific Holdings and Boston Scientific Group plc Sign MOU to Broaden Collaboration

Fineline Cube Jun 19, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with...

Company Drug

Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study

Fineline Cube Jun 19, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase...

Company Deals

Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes

Fineline Cube Jun 19, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a...

Company Drug

Roche’s Evrysdi Receives NMPA Approval for Wider SMA Patient Age Range

Fineline Cube Jun 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that its blockbuster nervous system drug Evrysdi...

Company Drug

MicuRx Pharmaceuticals’ MRX-4/Contezolid Combo Receives Clinical Trial Approvals for Diabetic Foot Infection

Fineline Cube Jun 19, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced receiving clinical trial approvals for its...

Company Deals

AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies

Fineline Cube Jun 19, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based...

Company Drug

BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma

Fineline Cube Jun 16, 2023

China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...

Company Drug

Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC

Fineline Cube Jun 16, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...

Company Drug

CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment

Fineline Cube Jun 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published...

Company Drug

Takeda and HutchMed’s Elunate Study Results Published in The Lancet

Fineline Cube Jun 16, 2023

Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...

Company Deals

Gates Foundation Renews Partnership with Beijing and Tsinghua to Boost Infectious Disease Research

Fineline Cube Jun 16, 2023

The Bill & Melinda Gates Foundation has announced the renewal of its collaboration with the...

Company Deals

Grifols AS Plans to Sell Stake in Shanghai RAAS Blood Products Co., Ltd for Up to $1.5 Billion

Fineline Cube Jun 16, 2023

Spain-based Grifols AS (NASDAQ: GRFS), a leading global player in the blood products industry, has...

Company Deals Digital

Sperogenix Therapeutics and LUCA Healthcare Join Forces to Advance Digital Therapy for Myasthenia Gravis

Fineline Cube Jun 16, 2023

China-based rare disease specialist Sperogenix Therapeutics Limited has entered into a partnership with compatriot firm...

Company Drug

Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors

Fineline Cube Jun 16, 2023

China-based Jiangxi Jemincare Group has announced that it has received approval from the China National...

Posts pagination

1 … 551 552 553 … 704

Recent updates

  • Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
  • Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline
  • Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
  • Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
  • Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Company

Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline

Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.